【Member News】 Malaysia's Metro Medical Showcases 100% Freeze-Thaw Survival Rate at Global Conference

On September 5, 2025, the 7th Global Assisted Reproduction Exchange Conference concluded successfully in Guangzhou. As an important part of the conference focusing on "Transnational Reproductive Medical Collaboration," Ms. Li Dan, China Director of Metro Reproductive Medical Group (stock code: 03005 KLSE), Malaysia, was invited to deliver a special speech entitled "Technology Leadership·Global Collaboration: Metro Medical Group's Innovative Practices in Assisted Reproduction in Malaysia." Relying on the group's 36 years of experience in assisted reproduction and its global technology layout, Director Li Dan comprehensively demonstrated Metro Medical Group's efforts in assisted pregnancy for elderly people, fertility preservation, and PGT technology applications from four dimensions: development history, core technologies, policy advantages, and China market services. Outstanding achievements in fields such as technology application provide an authoritative reference for China families to seek assisted reproductive services in Southeast Asia.

36 years of deep cultivation: From gynecology clinics to Southeast Asia's "leader" in assisted reproduction

At the beginning of the speech, Director Li Dan sorted out the development context of Metro Medical Group in the form of a Timeline, showing its transformation from a single clinic to Malaysia's largest pioneer fertility center:

· 1989: Starting with a gynecologic clinic, it started exploring obstetrics and gynecology and fertility services, becoming the earliest institution in Malaysia to enter the field of assisted reproduction;

· 2004: Prospective use ICSI (Single Sperm Injection Technology) as the first choice for all IVF cases, and simultaneously introduce frozen embryo transfer technology to significantly improve fertilization and pregnancy rates;

· 2008: Cooperated with Klang Government Hospital to launch the "IVF Shared Care Plan" to promote the popularization of assisted reproductive technology and allow more families to enjoy high-quality medical services;

· 2015: It was the first to carry out three generations of test-tube babies PGT-A (embryonic chromosome screening) and PGT-M (single gene disease testing) in Malaysia, providing precise fertility assistance solutions for families with genetic diseases and elderly women;

· 2018: Listed on the Malaysian stock market LEAP (stock code: 03005 KLSE), becoming one of the few assisted reproduction institutions in Southeast Asia to achieve capitalized operations;

· 2020: Officially enter the China market, customize the cross-border pregnancy assistance service process based on the needs of China families, and establish cooperation with Indonesian institutions in the same year to start a regional layout;

· 2022-2024: Continuous technological breakthroughs-introducing sperm DNA fragmentation testing, establishing an NGS (Next Generation Sequencing) genetic testing laboratory, and cooperating with Professor Simon Fisher, the "father of IVF" in the UK to carry out ovarian tissue cryopreservation (OTC) technology, in 2024, it will be included in the relevant section of Time magazine's "Person of the Year" due to its high success rate.

"As of 2025, Metro Medical Group has opened 17 branches in Malaysia, covering core cities such as Klang (headquarters), Penang, Johor, and Malacca. It has a team of 30 experienced reproductive doctors and has served more than 100,000 families in total., becoming Malaysia's largest and most comprehensive assisted reproduction center." Director Li Dan emphasized that every step of the group's development focuses on "solving patient pain points and breaking through technical bottlenecks", which is also the key to its continued leadership in the assisted reproduction industry in Southeast Asia.

Three core technology highlights: Data witnesses hard power and solves difficult fertility problems

In the core part of the speech, Director Li Dan used authoritative data and technical details to interpret Metro Medical Group's "trump card technology", among which many indicators reached the world's leading level:

1. 100% embryo/blastocyst freeze-thawed survival rate: CRYOTEC JAPAN technology

"Frozen embryo technology is the 'lifeline' of assisted reproduction, especially for patients with low ovarian reserve and repeated failures." Director Li Dan introduced that Metro Medical Group has adopted Japan's CRYOTEC freezing technology to achieve 9 consecutive months in 2023 (February, March, May to July, and September to December) by accurately controlling the freezing rate and optimizing the freezing fluid formula. The 100% embryo/blastocyst freeze-thawed survival rate far exceeds the industry average (approximately 85%-90%).

This technical advantage is of great significance to elderly women in China: "We once served a 43-year-old China patient with an AMH of only 0.6ng/mL. Four eggs were taken to form 2 blastocysts. After cryopreservation for 6 months, they were thawed and transplanted, and the pregnancy was successful. A 100% survival rate means that every precious embryo can be preserved to the greatest extent, giving patients more chances of conception."

2. PGT technology: 95% euploid blastocyst screening rate, accurately avoiding genetic risks

In response to issues such as the high rate of chromosomal abnormalities in embryos in elderly women and family fertility concerns with genetic diseases, Metro Medical Group's PGT technology (third-generation test tube) has performed outstandingly-2023 data shows that its PGT-A euploid blastocyst screening rate reaches 95%, can accurately detect 23 pairs of chromosomes with numerical and structural abnormalities; PGT-M can screen for more than 200 single gene diseases (such as thalassemia, cystic fibrosis, etc.) and block the inheritance of the disease in families carrying the pathogenic gene.

Director Li Dan gave an example: "A China couple is both carriers of the thalassemia gene. Previously, the pregnancy was terminated twice due to fetal illness. Through Metro's PGT-M technology, we selected 2 euploid embryos from 5 blastocysts that did not carry the pathogenic gene. The first transfer was successful, and the baby was in good health after birth."

3. Ovarian tissue cryopreservation (OTC): the "future solution" for fertility preservation

In order to meet the fertility preservation needs of young cancer patients, working women and other groups, Metro Medical Group partnered with Professor Simon Fisher, founder of CARE Fertility, the UK's largest assisted reproduction group and the "father of IVF", to introduce ovarian tissue cryopreservation (OTC) technology. This technology surgically extracts part of women's ovarian tissue and cryopreservation it, and then thaws it for transplantation when there is a need for fertility in the future. It not only retains fertility, but also delays the arrival of menopause.

"In 2023, we performed OTC surgery on a 28-year-old China patient with breast cancer. The patient received chemotherapy after surgery. The ovarian tissue is currently in good condition, and the transplant process can be started after the treatment is over." Director Li Dan said that OTC technology has filled a gap in the field of fertility preservation in Southeast Asia and provided more women with "fertility backup" options.

In addition, the group's in vitro fertilization rate reaches 73%, which is higher than the global average (about 65%). These data together constitute Metro Medical Group's "technical moat."

Malaysia's policy advantages: convenience and compliance, lowering the threshold for cross-border pregnancy assistance for China families

In addition to technical strength, Malaysia's assisted reproduction policy is also an important reason for attracting China families. Director Li Dan explained in detail the advantages of local policies in his speech:

1. Strong compliance and transparent processes

Malaysia strictly supervises the assisted reproduction industry. All institutions need to be approved by the Ministry of Health, and technical standards are in line with international standards. As a listed company, Metro Medical Group is completely open and transparent in its service processes and charging standards, and there is no hidden consumption. China families can clearly understand every step of diagnosis and treatment through official channels.

2. Convenient cross-border services and barrier-free language communication

For China families, Metro Medical Group provides "special Chinese service classes", which include professional teams to connect with them, from preliminary consultation, visa assistance, medical translation to living arrangements in Malaysia. "China patients do not need to worry about language barriers. Most of our doctors and nurses have Chinese communication skills, and each patient will be equipped with a dedicated medical consultant to track the progress of diagnosis and treatment throughout the process."

3. Significant cost advantage and high cost performance

Compared with countries such as the United States and the United Kingdom, Malaysia's assisted reproduction costs are more competitive. Taking the third generation of IVF as an example, Metro Medical Group's single-cycle cost is about 80,000 - 100,000 yuan, which is only 1/3-1/2 of that of similar services in the United States. It can flexibly choose diagnosis and treatment plans based on patient needs, taking into account both effectiveness and cost.

Exclusive services for the China market: from "cross-border diagnosis and treatment" to "full escort"

Since entering the China market in 2020, Metro Medical Group has always focused on the needs of China families and created a "one-stop cross-border pregnancy assistance service system." Director Li Dan introduced that the system mainly includes three major modules:

1. Early stage: Personalized evaluation and plan customization

China families can communicate with Metro's senior doctors through online video consultation (equipped with Chinese translation). The doctor will formulate an exclusive assisted pregnancy plan based on the patient's age, AMH level, previous diagnosis and treatment history, etc. At the same time, the group provides domestic preliminary examination guidance to help patients complete basic physical examinations ahead of schedule and reduce their stay in Malaysia.

2. Mid-term: Diagnosis and treatment and living security in Malaysia

After patients go to Malaysia, the group provides airport pick-up, accommodation arrangements (close to the branch hospital and convenient transportation), and medical escort services to ensure a smooth diagnosis and treatment process. "We have cooperative apartments around Klang, Penang and other branches, equipped with Chinese life butlers, who can assist in processing telephone cards and bank cards, solve daily shopping, catering and other needs, and allow patients to focus on treatment."

3. Late stage: Follow-up and pregnancy management

After embryo transfer, patients can choose to return to China for recuperation. Metro Medical Group will establish diagnosis and treatment docking with local hospitals in China to provide remote follow-up guidance; if you are waiting for the results of pregnancy tests in Malaysia, a professional medical team will also provide pregnancy care advice to ensure the safety of mother and infant.

"As of 2025, we have provided cross-border assisted pregnancy services to more than 2000 China families. Among them, the pregnancy rate for patients over 35 years old reaches 58%, and the clinical pregnancy rate for PGT cycles reaches 65%, which has been recognized by a large number of China families." Director Li Dan shared that many patients will actively recommend their relatives and friends to choose Metro after successful conception, which is the greatest affirmation of the group's services and technology.

Future outlook: Deepen China-Malaysia cooperation to make high-quality assisted reproductive resources within reach

At the end of the speech, Director Li Dan said that Metro Medical Group will continue to deepen the docking with China market in the future: on the one hand, strengthen technical exchanges and cooperation with China reproductive medical institutions, combine Malaysia's PGT technology and frozen embryo technology with China's clinical experience to jointly promote the development of assisted reproduction industry; On the other hand, in response to the needs of China families, cross-border service processes have been optimized and a full-cycle service of "fertility assessment + pregnancy assistance diagnosis and treatment + postpartum follow-up" has been launched, so that more China families can enjoy high-quality medical services that are synchronized with Malaysia without having to travel far overseas.

"Assisted reproduction is not only a transfer of technology, but also a transfer of hope. Metro Medical Group is willing to use its 36 years of technical accumulation and service experience to build a bridge to 'good pregnancy' for China families, so that every fertility dream can be realized under professional protection." Director Li Dan's speech ended and aroused a strong resonance among the audience.